"The cumulative odds ratio (OR) and incidence rate ratio (IRR) were significantly higher in antipsychotic-exposed youth compared with healthy control persons (OR, 2.58; 95% confidence interval [CI], 1.56-4.24; IRR, 3.02; 95% CI, 1.71 - 5.35; for b"...
There were no reports of overdose during the clinical development program of INVOKANA (canagliflozin).
In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment as dictated by the patient’s clinical status. Canagliflozin was negligibly removed during a 4-hour hemodialysis session. Canagliflozin is not expected to be dialyzable by peritoneal dialysis.
- History of a serious hypersensitivity reaction to INVOKANA, such as anaphylaxis or angioedema [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end stage renal disease (ESRD), or patients on dialysis [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Last reviewed on RxList: 2/17/2017
Additional Invokana Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.